HLS Therapeutics Net Income Over Time
| HLS Stock | CAD 4.48 0.17 3.66% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out HLS Therapeutics Performance and HLS Therapeutics Correlation. HLS |
Cross Equities Net Income Analysis
Compare HLS Therapeutics and related stocks such as Cannara Biotech, Cardiol Therapeutics, and Auxly Cannabis Group Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LOVE | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (12.3 M) | (12.5 M) | (1.5 M) | 2.3 M | 6.9 M | 6.4 M | 13.1 M | 15 M | 15.8 M |
| CRDL | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (15.9 M) | (14 M) | (20.6 M) | (24.7 M) | (11.5 M) | (28.1 M) | (36.7 M) | (33 M) | (31.4 M) |
| XLY | (15.6 K) | 84.3 K | 105.2 K | 62.3 K | 37.3 K | 32.5 K | (229.6 K) | (18.2 M) | (67 M) | (108.6 M) | (87.4 M) | (45.9 M) | (130.3 M) | (44.5 M) | (16.3 M) | (14.7 M) | (15.4 M) |
| HBP | (7.7 M) | (17.4 M) | (1.6 M) | (8.7 M) | (8.7 M) | (9.7 M) | (10.1 M) | (8.7 M) | (7.5 M) | (9 M) | (7.9 M) | (6.1 M) | (6.3 M) | (9.3 M) | (5.2 M) | (6 M) | (6.3 M) |
| RX | (600 K) | 420.4 K | 1.5 M | 1.9 M | 3.2 M | 3.8 M | 4.3 M | 5.2 M | 5.7 M | 4.4 M | 3.8 M | 6.3 M | 5.5 M | 6.5 M | 7.3 M | 8.4 M | 8.8 M |
| QIPT | (34.1 K) | (548 K) | (2.5 M) | (1.4 M) | (18.3 M) | (57.4 M) | (19.2 M) | 14.5 M | (5.6 M) | (4.6 M) | (6.2 M) | 4.8 M | (2.8 M) | (6.8 M) | (10.7 M) | (9.6 M) | (9.1 M) |
HLS Therapeutics and related stocks such as Cannara Biotech, Cardiol Therapeutics, and Auxly Cannabis Group Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in HLS Therapeutics financial statement analysis. It represents the amount of money remaining after all of HLS Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| HLS Therapeutics | HLS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 10 Carlson Court, |
| Exchange | Toronto Exchange |
CAD 4.48
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.